کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
2136625 | 1087805 | 2014 | 7 صفحه PDF | دانلود رایگان |
• An impairment of notch1 deactivation in MM-MSCs was found.
• CFZ promoted osgeogenic potential of MM-MSCs.
• CFZ stimulates osteogenesis via notch1 inhibition in MSCs.
Notch1 signaling plays a key role in the differentiation of mesenchymal stem cells (MSCs). Carfilzomib (CFZ), a second-generation proteasome inhibitor, has potent cytotoxicity against myeloma cells. In this study, we investigated the effects of CFZ on the osteogenic differentiation potential of MSCs derived from myeloma patients (MM-MSCs) in vitro. MM-MSCs showed decreased osteogenic differentiation ability, together with an impairment of notch1 deactivation. The notch1 inhibitor DAPT and the downregulation of notch1 by shRNA promoted osteogenesis in MM-MSCs. Additionally, CFZ treatment resulted in notch1 inhibition and enhanced osteogenesis in MM-MSCs. These findings suggest that CFZ stimulates osteogenesis via notch1 inhibition.
Journal: Leukemia Research - Volume 38, Issue 8, August 2014, Pages 970–976